IP Library Assignment 058566/0170
Patent Assignment
Reel/Frame 058566/0170

Change of Name

Recorded: 2021-11-23 Pages: 27
Assignor
GEMOAB MONOCLONALS GMBH
Executed: 2020-09-04
Assignee
GEMOAB GMBH
TATZBERG 47, DRESDEN, 01307, GERMANY
Covered Properties (12)
Universal Chimeric Antigen Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders
Application: 16/798,255 →
Publication: US 2021/0206828
Genetic Modified Pluri- or Multipotent Stem Cells and Uses Thereof
Application: 17/157,260 →
Publication: US 2021/0284729
Targeting Modules for Universal Chimeric Antigen Receptor Expressing Immune Cells and Use in the Treatment of Cancer Infections and Autoimmune Disorders
Application: 16/618,881 →
Publication: US 2020/0131262
Reversed Universal Chimeric Antigen Receptor Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders
Application: 17/251,447 →
Publication: US 2021/0309751
Universal Chimeric Antigen Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders
Application: 15/504,012 →
Publication: US 2017/0240612
Universal Chimeric Antigen Expressing Immune Cells for Targeting of Diverse Multiple Antigens and Method of Manufacturing the Same and Use of the Same for Treatment of Cancer, Infections and Autoimmune Disorders
Application: 16/513,672 →
Publication: US 2019/0352370
An Isolated Human Mesenchymal Stem Cell Expressing a Bispecific Antibody That Binds CD33 and CD3 and Method of Using to Treat Cancer
Application: 16/102,071 →
Publication: US 2019/0040134
Anti-CD33 Antibodies and Use Thereof for Immunotargeting in Treating CD33-Associated Illnesses
Patent: 8,759,494 →
Application: 13/497,800 →
Publication: US 2012/0251554
Anti-La Antibodies and Their Use for Immunotargeting
Patent: 9,540,446 →
Application: 13/814,510 →
Publication: US 2013/0216544
Antibodies against prostate-specific stem cell antigen and use thereof
Patent: 9,200,078 →
Application: 14/129,933 →
Publication: US 2014/0134155
An Isolated Human Mesenchymal Stem Cell Expressing a Bispecific Antibody That Binds CD33 and CD3
Application: 14/959,784 →
Publication: US 2016/0159909
Anti-La Antibodies and Their Use for Immunotargeting
Application: 15/355,060 →
Publication: US 2017/0158774
Related Assignments (21)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 2, 2012
From: BACHMANN, MICHAEL; STAMOVA, SLAVA
To: TECHNISCHE UNIVERSITAET DRESDEN
Reel/Frame 028307/0601 →
Assignment of Assignor's Interest May 3, 2013
From: BACHMANN, MICHAEL
To: TECHNISCHE UNIVERSITAET DRESDEN
Reel/Frame 030341/0576 →
Assignment of Assignor's Interest Dec 28, 2013
From: BACHMANN, MICHAEL
To: TECHNISCHE UNIVERSITAET DRESDEN
Reel/Frame 031855/0862 →
Assignment of Assignor's Interest Mar 12, 2014
From: TECHNISCHE UNIVERSITAET DRESDEN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 032411/0131 →
Change of Address Oct 29, 2014
From: TECHNISCHE UNIVERSITAET DRESDEN
To: TECHNISCHE UNIVERSITAET DRESDEN
Reel/Frame 034087/0041 →
Assignment of Assignor's Interest Dec 3, 2014
From: TECHNISCHE UNIVERSITAET DRESDEN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 034352/0546 →
Assignment of Assignor's Interest Dec 17, 2015
From: EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 037319/0053 →
Assignment of Assignor's Interest Nov 23, 2016
From: BACHMANN, MICHAEL
To: TECHNISCHE UNIVERSITAET DRESDEN
Reel/Frame 040413/0640 →
Assignment of Assignor's Interest Nov 23, 2016
From: TECHNISCHE UNIVERSITAET DRESDEN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 040413/0721 →
Change of Address Nov 23, 2016
From: TECHNISCHE UNIVERSITAET DRESDEN
To: TECHNISCHE UNIVERSITAET DRESDEN
Reel/Frame 040680/0839 →
Assignment of Assignor's Interest Sep 15, 2017
From: BACHMANN, MICHAEL; EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 043602/0138 →
Assignment of Assignor's Interest Aug 13, 2018
From: EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 046630/0120 →
Assignment of Assignor's Interest Dec 3, 2019
From: EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 051163/0010 →
Assignment of Assignor's Interest Feb 18, 2020
From: BACHMANN, MICHAEL; EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 051851/0079 →
Assignment of Assignor's Interest Apr 19, 2020
From: BACHMANN, MICHAEL; EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 052436/0024 →
Assignment of Assignor's Interest Dec 11, 2020
From: BACHMANN, MICHAEL
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 054617/0820 →
Assignment of Assignor's Interest Jan 25, 2021
From: EHNINGER, ARMIN
To: GEMOAB MONOCLONALS GMBH
Reel/Frame 055022/0250 →
Change of Name Mar 17, 2022
From: GEMOAB GMBH
To: AVENCELL EUROPE GMBH
Reel/Frame 059390/0606 →
Change of Name May 26, 2022
From: GEMOAB GMBH
To: AVENCELL EUROPE GMBH
Reel/Frame 060202/0628 →
Security Interest Jan 4, 2024
From: AVENCELL THERAPEUTICS, INC.
To: BXLS V - DIAMANT L.P., AS COLLATERAL AGENT
Reel/Frame 066026/0610 →
Release of Security Interest Oct 18, 2024
From: BXLS V – DIAMANT L.P.
To: AVENCELL THERAPEUTICS, INC.
Reel/Frame 068941/0187 →